China's API Industry Shifts from Price Wars to Value Competition Amid Supply Chain Reshuffle

As the global pharmaceutical supply chain undergoes profound restructuring, China's active pharmaceutical ingredients (API) sector has reached a critical inflection point. Having moved away from the former 'price war'–driven red ocean, the industry is now transitioning into a 'value war' phase. As a cornerstone of China's pharmaceutical manufacturing system, the API sector is demonstrating stronger resilience and renewed growth momentum.

Industry Bottoms Out and Rebounds, Resilience Becomes Evident

After a short-term adjustment in 2023 caused by global destocking and intensified competition, China's API industry began to show clear recovery signals during 2024–2025.

In 2024, industry revenue stabilised at RMB 424.15 billion, with growth turning marginally positive at 0.3%, indicating that the adjustment phase was nearing its end. By 2025, recovery became more pronounced: in the first half of the year, both revenue and profit recorded growth of 1.5% and 5.6% respectively. The notably faster increase in profits than in revenue points to an improvement in overall profitability.

From January to September 2025, cumulative production of chemical drug substances reached 2.721 million tonnes, up 1.2% year on year. Despite periodic monthly fluctuations, overall operations have returned to a reasonable range, providing a foundation for stable development.

Structural Differentiation Deepens, Specialisation Accelerates

The industry has moved beyond the era of extensive growth, forming a clearly differentiated three-tier structure with distinct competitive logics.

At the base are bulk APIs, including antibiotics, vitamins and antipyretic analgesics. This segment is characterised by high production concentration, large scale and pronounced price cyclicality, with competition centred on cost and scale advantages.

The middle tier comprises specialty APIs targeting chronic diseases such as cardiovascular conditions, diabetes and oncology. This segment features higher technical barriers and greater value-added potential. Companies such as Huahai and Tianyu have successfully upgraded from bulk APIs to specialty APIs, securing positions in international high-end markets.

At the apex are patented APIs and CDMO services, the most growth-oriented segment serving global innovative drug R&D. Driven by rising outsourcing demand for innovative medicines, this segment is expected to maintain annual growth of over 15% by 2025. Leading firms, including WuXi AppTec and Asymchem, have embedded themselves in advanced global innovation chains through high-end international contracts.

Three Competitive Camps Take Shape with Divergent Strategies

Ongoing restructuring has forced enterprises to make strategic choices, giving rise to three distinct competitive camps.

The first comprises full-chain giants such as Huahai Pharmaceutical and Apeloa Pharmaceutical. Through long-term accumulation, these companies have built vertically integrated systems spanning APIs to finished dosage forms. Their advantages lie in cost reduction and supply security enabled by industrial chain synergies, supported by internationally recognised quality certifications that facilitate global market access.

The second camp consists of niche market champions that avoid direct competition with large players by excelling in specialised fields. Jiuzhou Pharmaceutical, for example, has become a specialist in small-molecule CDMO services through deep cooperation with multinational pharmaceutical companies, while SINOPEC Biotech and ShengNuo Biology have capitalised on the GLP-1 weight-loss drug trend to establish themselves as key peptide API suppliers. Their competitiveness is rooted in specialised expertise and long-term client relationships.

The third camp includes technological frontier pioneers such as Aurisco and Porton, which are positioning themselves in emerging platforms like small nucleic acid therapeutics and continuous flow synthesis. These firms seek to capture opportunities in the next industrial upgrade by leveraging technological generational gaps.

Foreign Trade Shifts Toward Quality and Technology

Foreign trade data provides a key lens for assessing competitiveness. From January to September 2025, China's total API imports and exports reached US$41.55 billion, up 4.7% year on year, reflecting a broadly positive trend.

A notable turning point emerged in the first half of 2025, as the two-year strategy of trading profit for volume came to an end. Export prices rose by 0.5% year on year, signalling a shift away from price-based competition toward quality and technological capability.

Product performance varied significantly. Vitamin exports rose sharply, with vitamin E up 68.0%, benefiting from overseas capacity constraints. Hormone exports increased by 21.8% amid strong demand, while antibiotic exports declined by 9.1% overall due to weak demand and internal structural divergence.

By market, Asia and Europe together accounted for 74% of exports, with India and the United States remaining the two largest single markets. However, import data underscores structural challenges. In the first half of 2025, China's API imports from Denmark increased by 27.8%, consolidating its position as China's largest API supplier through advanced biopharmaceutical technologies. This highlights continued dependence on imports for high-value, high-barrier patented APIs and biologics, an issue that remains a key obstacle to further upgrading.

Looking ahead, future success will favour enterprises that clearly define their positioning—whether through full-chain ecosystem construction, leadership in niche segments, or breakthroughs in cutting-edge technologies. At the same time, addressing shortcomings in high-value patented APIs will be critical to China's transition from a major API producer to a true industry leader. As a foundation of the national healthcare system, the API industry continues to reflect the resilience and ingenuity underpinning China's manufacturing upgrade.